President-elect Donald Trump’s lawyers urge judge to toss his hush money convictionLong-stalled economic development bill nears finish line
1 2 3 Kolkata: Online violence against women was cited as one of the "upcoming" threats against the dignity and safety of women by Amrita Dasgupta of NGO Swayam during a discussion organised by the Bengal Obstetric and Gynaecology Society (BOGS). In response to the question of moderator Dr Jaita Chakrabarti's question — if there was a change in how violence against women takes place in their respective fields of expertise — Dasgupta stressed the use of technology on social media platforms to threaten women. Morphing of women's images and using it for " revenge porn " was one of the examples cited by Dasgupta as means used by predators to cause harm. A report published by the United Nations Women in 2022 stated that the prevalence of online and technology-facilitated violence against women and girls ranges from 16% to 58% across the globe. According to the report, such acts of violence include sexual harassment, stalking and zoom bombing, which is the practice of disrupting a video-conference call and showing "racially charged or sexually explicit material to the unexpecting participants". A human rights practitioner at Calcutta High Court, Mrinalini Majumdar, highlighted the need for a legislative mechanism to manage an individual's behaviour on social media platforms.
Daiwa Securities Group Inc. raised its position in Smith Douglas Homes Corp. ( NYSE:SDHC – Free Report ) by 31.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,487 shares of the company’s stock after acquiring an additional 7,015 shares during the period. Daiwa Securities Group Inc. owned approximately 0.06% of Smith Douglas Homes worth $1,114,000 as of its most recent filing with the Securities & Exchange Commission. Other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Smith Douglas Homes in the third quarter valued at approximately $34,000. RiverPark Advisors LLC acquired a new stake in Smith Douglas Homes in the second quarter valued at approximately $120,000. Atria Investments Inc acquired a new stake in Smith Douglas Homes in the third quarter valued at approximately $204,000. Portside Wealth Group LLC purchased a new position in shares of Smith Douglas Homes in the third quarter worth $283,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Smith Douglas Homes in the third quarter worth $349,000. Insider Buying and Selling In other news, Director Jeffrey T. Jackson acquired 8,605 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average price of $29.77 per share, with a total value of $256,170.85. Following the completion of the acquisition, the director now owns 15,748 shares of the company’s stock, valued at approximately $468,817.96. This represents a 120.47 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website . Smith Douglas Homes Price Performance Analysts Set New Price Targets A number of research analysts have issued reports on SDHC shares. JPMorgan Chase & Co. cut shares of Smith Douglas Homes from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $41.00 to $36.00 in a report on Monday, November 25th. Wells Fargo & Company raised their price target on shares of Smith Douglas Homes from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Wedbush reaffirmed a “neutral” rating and issued a $20.00 price target on shares of Smith Douglas Homes in a report on Tuesday, November 12th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $26.00 price target on shares of Smith Douglas Homes in a report on Thursday, August 15th. Finally, Bank of America raised their price target on shares of Smith Douglas Homes from $36.00 to $40.00 and gave the stock a “neutral” rating in a report on Thursday, September 19th. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Smith Douglas Homes presently has a consensus rating of “Hold” and a consensus price target of $32.40. Get Our Latest Stock Report on SDHC Smith Douglas Homes Profile ( Free Report ) Smith Douglas Homes Corp., together with its subsidiaries, engages in the design, construction, and sale of single-family homes in the southeastern United States. It also provides closing, escrow, and title insurance services. The company sells its products to entry-level and empty-nest homebuyers. Smith Douglas Homes Corp. Featured Articles Want to see what other hedge funds are holding SDHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith Douglas Homes Corp. ( NYSE:SDHC – Free Report ). Receive News & Ratings for Smith Douglas Homes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith Douglas Homes and related companies with MarketBeat.com's FREE daily email newsletter .Iowa readies for Nebraska, Ferentz says Huskers ‘turning the corner’ under second-year coach
Lumina Gold Announces Concession Extension Until 2049NFL Weather Forecast Week 13: Will wind, rain, or snow impact fantasy football start 'em, sit 'em decisions? | Sporting NewsCharles Schwab Investment Management Inc. decreased its holdings in shares of Alkermes plc ( NASDAQ:ALKS – Free Report ) by 11.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,107,049 shares of the company’s stock after selling 275,518 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.30% of Alkermes worth $58,976,000 at the end of the most recent quarter. Several other hedge funds have also recently added to or reduced their stakes in ALKS. Intech Investment Management LLC bought a new stake in shares of Alkermes in the third quarter valued at approximately $1,463,000. Moors & Cabot Inc. acquired a new position in Alkermes during the 3rd quarter valued at $223,000. Advisors Asset Management Inc. raised its stake in Alkermes by 21.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 10,158 shares of the company’s stock valued at $284,000 after purchasing an additional 1,771 shares during the last quarter. Pathstone Holdings LLC boosted its holdings in Alkermes by 72.8% in the 3rd quarter. Pathstone Holdings LLC now owns 71,324 shares of the company’s stock valued at $1,996,000 after purchasing an additional 30,048 shares during the period. Finally, AMG National Trust Bank grew its position in Alkermes by 68.3% in the 3rd quarter. AMG National Trust Bank now owns 59,645 shares of the company’s stock worth $1,669,000 after purchasing an additional 24,200 shares during the last quarter. Institutional investors own 95.21% of the company’s stock. Alkermes Stock Performance NASDAQ ALKS opened at $29.02 on Friday. Alkermes plc has a 1-year low of $22.90 and a 1-year high of $32.88. The company has a 50 day moving average of $28.01 and a 200-day moving average of $26.52. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The firm has a market cap of $4.70 billion, a price-to-earnings ratio of 14.88, a PEG ratio of 0.97 and a beta of 0.47. Insider Activity at Alkermes Analysts Set New Price Targets ALKS has been the subject of a number of research analyst reports. Mizuho upped their price objective on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group decreased their price objective on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. lowered their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Cantor Fitzgerald reduced their target price on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Finally, Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and boosted their price target for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of “Moderate Buy” and an average price target of $35.42. Read Our Latest Stock Analysis on ALKS Alkermes Company Profile ( Free Report ) Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Featured Stories Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc ( NASDAQ:ALKS – Free Report ). Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter .
Google Maps under scrutiny after fatal car accident in India
Doughty scores 17 in Indiana State's 83-80 win against IonaDirector Christopher Nolan is one of the finest directors we have in Hollywood today and for good reason. The British-American director has given us some of the best movies in recent memory including the likes of Interstellar, Inception, Memento , and more recently movies like Tenet and Oppenheimer . So when Universal studios announced an all-new film from the director, we were excited. Also Read: Joaquin Phoenix was offered to play Joker in Christopher Nolan's 'The Dark Knight'; Here's why he rejected it In a post on social media platform X (formerly Twitter), the studio’s official handle shared that the director is all set to make a new movie based on ancient Greek poet Homer’s epic poem ‘Odyssey’. The movie will be shot completely in IMAX and is set for a July 2026 release according to the studio. Christopher Nolan’s next film ‘The Odyssey’ is a mythic action epic shot across the world using brand new IMAX film technology. The film brings Homer’s foundational saga to IMAX film screens for the first time and opens in theaters everywhere on July 17, 2026.— Universal Pictures (@UniversalPics) December 23, 2024 The studio also shared that the movie will be an ‘epic action film’. Safe to say, we are excited. However, what exactly is 'The Odyssey' anyway? Don’t worry, we got you covered. Odyssey is one of two epic poems attributed to ancient Greek poet Homer, the other being Iliad . While Iliad is based on the Trojan War, Odyssey details Greek hero King Odysseus’s journey back home to Ithaca after the ten year Trojan War. The poem recounts the various perils the king faced on his journey. Like Iliad, Odyssey too is divided into 24 books. The poem is regarded as one of the oldest known pieces of literature and has previously been adapted into several works in the media including 1954’s Ulysses with actor Kirk Douglas. There was also a movie called O Brother, Where Art Thou? released in the year 2000. Most recently, Italian director Uberto Pasolini released a film titled The Return (2024) starring actor Ralph Fiennes and Juliette Binoche. The Return is said to be based on the final sections of Homer’s magnum opus. So, what else do we know? According to several reports in the media, Nolan has casted an ensemble of actors for the film including Matt Damon, Robert Pattinson, Lupita Nyong’o, Tom Holland as well as Anne Hathaway, Charlize Theron and even Zendaya. While Robert Pattinson, Matt Damon and Anne Hathaway have all previously worked with the director in projects like Interstellar and Tenet , it’ll be the first time we see Tom Holland and Zendaya work with Nolan. Christopher Nolan’s next film is an adaption of ‘THE ODYSSEY’ • Described as a mythic action epic that follows the tale of Odysseus & his 10-year journey home after the Trojan War • Starring Tom Holland, Zendaya, Anne Hathaway, Matt Damon, Lupita Nyong’o and Robert Pattinson pic.twitter.com/5ugTNJlCxY — DiscussingFilm (@DiscussingFilm) December 23, 2024 There's not a lot of other information available about the roles these actors will play or other members of the cast, but it’s safe to assume that we’re getting a movie unlike anything else we’ve seen from Christopher Nolan before. As it is, the director has previously directed movies that dealt with science fiction and/or action, The Odyssey will be Nolan’s maiden voyage into mythological films, and that alone is reason enough to be excited. As far as the shooting goes, reports suggest it’ll begin sometime next year. Nolan is also set to write the movie and will co-produce it alongside producer and wife Emma Thomas under their production house Syncopy Inc. With a stellar cast and epic storyline and the classic Christopher Nolan touch, the movie shows a lot of promise and we are excited, to say the least. For now, we’ll just have to wait and see how it all unfolds. Also Read: Christopher Nolan's next film titled 'The Odyssey'; Here's when it will release
None8 ASX All Ords shares upgraded to 'strong buy' ratings in November